Annexin A2 (D11G2) Rabbit mAb #8235
- WB
- IHC
- IF
- F
Supporting Data
REACTIVITY | H M R Mk B Pg |
SENSITIVITY | Endogenous |
MW (kDa) | 38 |
Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IHC-Immunohistochemistry
- IF-Immunofluorescence
- F-Flow Cytometry
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
- Mk-Monkey
- B-Bovine
- Pg-Pig
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Simple Western™ | 1:50 - 1:250 |
Immunohistochemistry (Paraffin) | 1:200 - 1:800 |
Immunofluorescence (Immunocytochemistry) | 1:100 - 1:200 |
Flow Cytometry (Fixed/Permeabilized) | 1:50 - 1:200 |
Storage
For a carrier free (BSA and azide free) version of this product see product #71123.
Protocol
Specificity / Sensitivity
Annexin A2 (D11G2) Rabbit mAb recognizes endogenous levels of total annexin A2 protein. This antibody is not known or predicted to cross-react with other annexin family members.
Species Reactivity:
Human, Mouse, Rat, Monkey, Bovine, Pig
The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.
Species predicted to react based on 100% sequence homology:
Dog, Horse
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Phe307 of human annexin A2 protein.
Background
Annexin A2 (ANXA2), also known as lipocortin II or calpactin-1 heavy chain, is a 36 kDa member of the annexin superfamily that binds phospholipids and other proteins in a calcium-dependent manner via annexin repeats (1). Annexin A2 contains four such repeats through which it mediates protein-protein and protein-lipid interactions (1-4). It forms a constitutive heterotetramer with S100A10, acting as a bridge between the actin cytoskeleton, plasma membrane, and endocytotic vesicle machinery (5-7). Originally identified as a protein inhibitor of phospholipase A2, annexin A2 has subsequently been shown to interact with an array of protein and non-protein partners, including F-actin, spectrin, SNARE complexes, RNA, and virus particles (4,6,8,9). Annexin A2 has also been shown to have receptor-like activity and is detected on the surface of macrophages and vascular endothelial cells where it mediates macrophage activation and Factor Xa signaling, respectively (10-13). Upregulation of annexin A2 at the cell surface is thought to be modulated by phosphorylation at Tyr23 by Src (14-18). Interestingly, phosphorylation at Tyr23 has recently been shown to be required for cell surface expression of annexin A2 where it mediates motility, invasiveness, and overall metastatic potential of certain pancreatic cancer cells (19,20). Annexin A2 has also been shown to be heavily phosphorylated on serine residues in response to PKC activation via a pleiotropic mechanism (21-23). For a complete list of curated phosphorylation sites on annexin A2, please see PhosphoSitePlus® at www.phosphosite.org.
- Barton, G.J. et al. (1991) Eur J Biochem 198, 749-60.
- Gerke, V. and Weber, K. (1985) EMBO J 4, 2917-20.
- Glenney, J.R. and Tack, B.F. (1985) Proc Natl Acad Sci USA 82, 7884-8.
- Gerke, V. and Weber, K. (1984) EMBO J 3, 227-33.
- Illien, F. et al. (2010) Biochim Biophys Acta 1798, 1790-6.
- Umbrecht-Jenck, E. et al. (2010) Traffic 11, 958-71.
- Jung, M.J. et al. (2010) Exp Cell Res 316, 1234-40.
- Filipenko, N.R. et al. (2004) J Biol Chem 279, 8723-31.
- Wright, J.F. et al. (1994) Biochem Biophys Res Commun 198, 983-9.
- Bhattacharjee, G. et al. (2008) Circ Res 102, 457-64.
- Pizzo, S.V. (2008) Circ Res 102, 389-91.
- Swisher, J.F. et al. (2007) J Leukoc Biol 82, 1174-84.
- Deora, A.B. et al. (2004) J Biol Chem 279, 43411-8.
- Huang, K.S. et al. (1986) Cell 46, 191-9.
- Erikson, E. et al. (1984) Mol Cell Biol 4, 77-85.
- Glenney, J.R. (1985) FEBS Lett 192, 79-82.
- Morel, E. and Gruenberg, J. (2009) J Biol Chem 284, 1604-11.
- de Graauw, M. et al. (2008) Mol Cell Biol 28, 1029-40.
- Nedjadi, T. et al. (2009) Br J Cancer 101, 1145-54.
- Zheng, L. et al. (2011) PLoS One 6, e19390.
- Gould, K.L. et al. (1986) Mol Cell Biol 6, 2738-44.
- Luo, W. et al. (2008) Mol Carcinog 47, 934-46.
- He, K.L. et al. (2011) J Biol Chem 286, 15428-39.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.